Supplementary data1 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors

Q: What type of study is this?

This is a Phase 1 study (also classified as: Phase 2).

Omid Hamid; Dana B. Cardin; F. Stephen Hodi; Patricia LoRusso; Taha Merghoub; Roberta Zappasodi; Rachana Maniyar; John E. Janik; Manfred Velden; Feng Zhou; Zhiwan Dong; Xuejun Chen; James J. Harding

doi:10.1158/1078-0432.30255713

October 1, 2025Open Access

Supplementary data1 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors

View Full Paper

Ask AI

Bookmark

Share

Key Points

INCAGN01876 shows promise in treating patients with advanced or metastatic solid tumors, enhancing therapeutic options.
The phase I/II study aims to assess safety and efficacy, demonstrating initial supportive data for future research.
A thorough evaluation of the glucocorticoid-induced tumor necrosis factor receptor agonist highlights its potential impact on treatment protocols.
Results from this study may inform subsequent trials, emphasizing the need for further investigation in diverse patient populations.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

First-in-human trial evaluates efficacy of a glucocorticoid-induced tumor necrosis factor receptor agonist in metastatic solid tumors, suggesting potential therapeutic benefits.

Abstract

Supplementary materials

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hamid et al. (2025) studied this question.

synapsesocial.com/papers/68e040f7a99c246f578b3d70 https://doi.org/10.1158/1078-0432.30255713

View Full Paper

Ask AI

Bookmark

Share

Supplementary data1 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors

Key Points

No abstract yet

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Supplementary data1 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors

Key Points

No abstract yet

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading